Life Sciences 2026

2026 Medical Science Liaison Hiring Report

By Darren Nelson, Founder & CEO, Recruits Lab

Quick Answer

MSL hiring grew 27 percent year-over-year in 2025, concentrated in oncology, CNS, rare disease, and cell/gene therapy. Average MSL base ranges from $165K-$400K depending on therapeutic area and tenure. Time-to-fill averages 8-12 weeks; therapeutic area match is decisive.

Market data is directional and reflects Recruits Lab's proprietary 2024-2026 placement dataset combined with public benchmarks. Figures may vary by geography, company stage, industry, equity structure, bonus structure, and candidate experience. This report is an educational resource, not a definitive market survey.

Executive Summary

MSL demand grew sharply through 2025 as commercial-stage approvals expanded and clinical-stage biotech hired MSL teams earlier in the pre-launch sequence.

Oncology, CNS, rare disease, and cell/gene therapy are the tightest therapeutic areas. Cardiometabolic and immunology saw renewed growth from 2024 lows.

MSL teams are increasingly built in pre-launch waves: 2-3 senior MSLs hired 12-18 months pre-approval, expanded to full regional coverage 6-9 months pre-approval.

Field Medical Director and Sr Director MSL hiring grew alongside MSL team expansion. These roles increasingly require both KOL fluency and field team management experience.

Remote-first MSL roles remained dominant. Roughly 90 percent of our 2025 MSL placements were primarily field-based with quarterly home-office travel.

Hiring Demand

Pre-launch and recently launched commercial-stage biotech drove the majority of net-new MSL hiring. Mid-size pharma rebalanced existing teams; large pharma hiring was steady.

→Oncology MSL searches: 33 percent year-over-year growth.
→Rare disease MSL: 29 percent growth, anchored by gene therapy launches.
→CNS MSL: 24 percent growth driven by neurodegenerative pipeline activity.
→Cell and gene therapy MSL: 41 percent growth from a small base.
→Field Medical Director / Sr Director MSL: 19 percent growth.

Salary Trends

MSL base compensation rose 4-7 percent year-over-year in 2025. Oncology and rare disease commanded the largest premiums. Field Medical Director compensation rose faster as the role consolidated team management responsibility.

Level	Range	Notes
MSL (1-3 yrs)	$165K-$210K base + 15-20% bonus	—
Senior MSL	$200K-$270K base + 15-25% bonus	—
Executive MSL / Lead MSL	$240K-$310K base + 20-25% bonus	—
Field Medical Director	$290K-$400K base + 25-35% bonus	—

Candidate Availability

Tight

MSL talent supply is moderate at the entry level (transitioning PharmDs, PhDs, MDs from academia or fellowship) but tight at the Senior MSL level and very tight at Field Medical Director, particularly with cell/gene therapy experience.

Senior MSL with oncology launch experience: top 8 percent of demand
Cell/gene therapy MSL with prior launch: scarce — fewer than 200 candidates U.S.-wide
Average time-to-hire Senior MSL: 8-12 weeks
Counter-offer rate at Senior MSL+: ~45 percent

Time-to-Fill Benchmarks

Role	Typical Time-to-Fill	Notes
MSL (1-3 yrs)	6-10 weeks	—
Senior MSL	8-12 weeks	—
Executive MSL / Lead MSL	10-14 weeks	—
Field Medical Director	12-18 weeks	—

Geographic Hotspots

Market	Commentary
Northeast Corridor (Boston-NYC-Philadelphia)	Highest MSL density. Strong academic KOL networks.
California (SF Bay Area + LA + San Diego)	Strong oncology and cell/gene KOL coverage.
Midwest (Chicago, Cleveland, Minneapolis)	Anchored by academic medical centers.
Texas (Houston, Dallas, Austin)	MD Anderson and UT Southwestern anchor oncology coverage.
Southeast (Atlanta, Nashville, RTP)	Growing regional coverage. Cost-effective hiring base.

Recruiting Challenges

Therapeutic area match is decisive. Cross-therapeutic moves are rare and require senior advocacy.
Pre-launch hiring waves create concentrated demand spikes. Multiple sponsors compete for the same MSL pool in any quarter.
Cell/gene therapy MSL talent is structurally scarce. The pool grows only as approved products expand.
Field Medical Director searches now require both KOL fluency and team management evidence; pure individual contributor candidates rarely advance.

Recruits Lab Insights

Recruits Lab MSL placements with both prior MSL tenure and academic KOL relationships close 1.6x faster than candidates with only one of the two.
Pre-launch MSL searches that name the asset, indication, and lead investigator close 30 percent faster than open-ended mandates.
Field Medical Director searches that allow primary remote with quarterly travel close 25 percent faster than hybrid-near-HQ mandates.
Big pharma MSL alumni in their 18-30 month tenure window are our highest-volume source for senior MSL placements in 2025-2026.